---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-066956"
form_type: "8-K"
ticker: "PASG"
cik: "0001787297"
company_name: "Passage BIO, Inc."
filed_at: "2026-05-27T20:15:26+00:00"
generated_at: "2026-05-27T20:21:19.798834+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Passage Bio terminates Gemma collaboration and exits Philadelphia office lease with $2.3M fee

## Summary
- Terminated Gemma Biotherapeutics collaboration covering Huntington's disease and Temporal Lobe Epilepsy programs, effective May 21, 2026.
- Termination also eliminates options for four new CNS indications under the July 2024 agreement.
- Paid $2.3M to exit 37,000 sq ft office lease (originally expiring Dec 2031); company is remote-only.
- Subleases previously covered substantially all of that office space.

## SEC filing metadata
- accession: 0001104659-26-066956
- form_type: 8-K
- ticker: PASG
- cik: 0001787297
- company_name: Passage BIO, Inc.
- filed_at: 2026-05-27T20:15:26+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787297/000110465926066956/0001104659-26-066956-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787297/000110465926066956/pasg-20260521x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-066956
- JSON: https://secwatch.observer/filing/0001104659-26-066956.json
- Plain text: https://secwatch.observer/filing/0001104659-26-066956.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.